What is the first choice antibiotic for UTI?

First-line antibiotics for acute, uncomplicated urinary tract infections (UTIs) typically include: Fosfomycin. Nitrofurantoin. Trimethoprim or sulfamethoxazole (Bactrim)

What is best antibiotic for complicated urinary tract infection?

Both meropenem-vaborbactam and piperacillin-tazobactam are effective in treating complicated UTI and acute pyelonephritis, with the overall success rates of 98.4% and 95.6% respectively[10].

What is the drug of choice for UTI?

Drugs commonly recommended for simple UTIs include: Trimethoprim/sulfamethoxazole (Bactrim, Septra, others) Fosfomycin (Monurol) Nitrofurantoin (Macrodantin, Macrobid)

How long do you take IV antibiotics for UTI?

Your doctor will let you know. Typically, for an uncomplicated infection, you’ll take antibiotics for 2 to 3 days. Some people will need to take these medicines for up to 7 to 10 days. For a complicated infection, you might need to take antibiotics for 14 days or more.

How many people have familial combined hyperlipidaemia ( FCH )?

Familial Combined Hyperlipidaemia Familial Combined Hyperlipidaemia (FCH for short) is found in approximately 1 in 100 of the population. Typically both cholesterol and triglyceride levels are raised in the blood due to an overproduction of cholesterol and a delay in removing triglycerides.

Who is the author of familial combined hyperlipidemia?

What is familial combined hyperlipidemia? Author: Mary Ellen T Sweeney, MD; Chief Editor: Romesh Khardori, MD, PhD, FACP more…

Which is the best health category for hyperlipidemia?

This collection features the best content from AFP, as identified by the AFP editors, on hyperlipidemia and related issues, including dyslipidemia, hypercholesterolemia, hypertriglyceridemia, kidney disease, lipid disorders, metabolic syndrome, statins, and triglyceride levels.

What is the RACGP for familial hypercholesterolaemia?

Wiegman A, Gidding SS, Watts GF, et al. Familial hypercholesterolaemia in children and adolescents: Gaining decades of life by optimizing detection and treatment. Eur Heart J 2015;36 (36):2424–37. doi: 10.1093/eurheartj/ehv157.